These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

45 related articles for article (PubMed ID: 15662155)

  • 21. Lower weight gain with the orally disintegrating olanzapine than with standard tablets in first-episode never treated psychotic patients.
    Arranz B; San L; Dueñas RM; Centeno M; Ramirez N; Salavert J; Del Moral E
    Hum Psychopharmacol; 2007 Jan; 22(1):11-5. PubMed ID: 17191265
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The improvement of obsessive- compulsive symptoms in a patient with schizophrenia treated with clozapine.
    Kumar S; Ng B; Howie W
    Psychiatry Clin Neurosci; 2003 Apr; 57(2):235-6. PubMed ID: 12667173
    [No Abstract]   [Full Text] [Related]  

  • 23. Worsening of obsessive-compulsive symptoms following treatment with olanzapine.
    Morrison D; Clark D; Goldfarb E; McCoy L
    Am J Psychiatry; 1998 Jun; 155(6):855. PubMed ID: 9619164
    [No Abstract]   [Full Text] [Related]  

  • 24. Possible association between the -2548A/G polymorphism of the leptin gene and olanzapine-induced weight gain.
    Kang SG; Lee HJ; Park YM; Choi JE; Han C; Kim YK; Kim SH; Lee MS; Joe SH; Jung IK; Kim L
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Jan; 32(1):160-3. PubMed ID: 17804136
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drug safety evaluation of olanzapine/fluoxetine combination.
    Cristancho MA; Thase ME
    Expert Opin Drug Saf; 2014 Aug; 13(8):1133-41. PubMed ID: 24972823
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Olanzapine-induced diabetes in a seven-year-old boy.
    Courvoisie HE; Cooke DW; Riddle MA
    J Child Adolesc Psychopharmacol; 2004; 14(4):612-6. PubMed ID: 15662154
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Weight gain in newly diagnosed first-episode psychosis patients and healthy comparisons: one-year analysis.
    Strassnig M; Miewald J; Keshavan M; Ganguli R
    Schizophr Res; 2007 Jul; 93(1-3):90-8. PubMed ID: 17478082
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Body mass index and weight gain as alternative or complementary hypothesis to explain olanzapine concentration-dose ratio accumulation.
    Charpiat B
    Clin Drug Investig; 2009; 29(2):143-4; author reply 144. PubMed ID: 19133710
    [No Abstract]   [Full Text] [Related]  

  • 29. Spontaneous Ejaculations in an Adolescent With Olanzapine Use: Case Report.
    Yektaş Ç; Tufan AE
    Clin Neuropharmacol; 2016; 39(3):157-8. PubMed ID: 26882319
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Olanzapine abuse.
    Kumsar NA; Erol A
    Subst Abus; 2013; 34(1):73-4. PubMed ID: 23327507
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Excessive masturbation associated with olanzapine in a pediatric case.
    Hergüner S
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Oct; 34(7):1349-50. PubMed ID: 20600465
    [No Abstract]   [Full Text] [Related]  

  • 32. Early Lipid Metabolic Effects of the Anti-Psychotic Drug Olanzapine on Weight Gain and the Associated Gene Expression.
    Chen CC; Nakano T; Hsu LW; Chu CY; Huang KT
    Neuropsychiatr Dis Treat; 2022; 18():645-657. PubMed ID: 35355504
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Olanzapine orally disintegrating tablet: a review of efficacy and compliance.
    San L; Casillas M; Ciudad A; Gilaberte I
    CNS Neurosci Ther; 2008; 14(3):203-14. PubMed ID: 18801113
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term weight loss observed with olanzapine orally disintegrating tablets in overweight patients with chronic schizophrenia. A 1 year open-label, prospective trial.
    Chawla B; Luxton-Andrew H
    Hum Psychopharmacol; 2008 Apr; 23(3):211-6. PubMed ID: 18219624
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The antidepressant effects of risperidone and olanzapine in bipolar disorder.
    McIntyre RS; Mancini DA; Srinivasan J; McCann S; Konarski JZ; Kennedy SH
    Can J Clin Pharmacol; 2004; 11(2):e218-26. PubMed ID: 15520475
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Olanzapine: a 5-year perspective.
    Littrell KH; Petty RG; Wolf NM
    Expert Rev Neurother; 2006 Jun; 6(6):811-21. PubMed ID: 16784405
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adolescent weight loss during treatment with olanzapine.
    Cohen JA; Perel JM
    J Child Adolesc Psychopharmacol; 2004; 14(4):617-20. PubMed ID: 15662155
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Obsessive-compulsive symptoms with olanzapine.
    Alevizos B; Papageorgiou C; Christodoulou GN
    Int J Neuropsychopharmacol; 2004 Sep; 7(3):375-7. PubMed ID: 15231024
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.